What is the share price of Nureca Ltd (NURECA) today?
The share price of NURECA as on 17th February 2026 is ₹284.70. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Nureca Ltd (NURECA) share?
The past returns of Nureca Ltd (NURECA) share are- Past 1 week: 0.85%
- Past 1 month: -13.04%
- Past 3 months: 5.58%
- Past 6 months: 20.88%
- Past 1 year: 7.92%
- Past 3 years: -26.17%
- Past 5 years: -55.91%
What are the peers or stocks similar to Nureca Ltd (NURECA)?
The peers or stocks similar to Nureca Ltd (NURECA) include:What is the market cap of Nureca Ltd (NURECA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Nureca Ltd (NURECA) is ₹271.66 Cr as of 17th February 2026.What is the 52 week high and low of Nureca Ltd (NURECA) share?
The 52-week high of Nureca Ltd (NURECA) is ₹343 and the 52-week low is ₹203.62.What is the PE and PB ratio of Nureca Ltd (NURECA) stock?
The P/E (price-to-earnings) ratio of Nureca Ltd (NURECA) is 315.88. The P/B (price-to-book) ratio is 1.40.Which sector does Nureca Ltd (NURECA) belong to?
Nureca Ltd (NURECA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Nureca Ltd (NURECA) shares?
You can directly buy Nureca Ltd (NURECA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Nureca Ltd
NURECA Share Price
284.700.00% (+0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
NURECA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
NURECA Performance & Key Metrics
NURECA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 25.58 | 1.40 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.37 | 5.73 | 0.59% |
NURECA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
NURECA Company Profile
Nureca Ltd is engaged in the marketing of home healthcare & wellness products
SUNPHARMA
PE Ratio
37.70
37.70
1Y Return
0.17%
0.17%
Buy Reco %
94.44
94.44
TORNTPHARM
PE Ratio
75.41
75.41
1Y Return
38.35%
38.35%
Buy Reco %
77.78
77.78
CIPLA
PE Ratio
20.59
20.59
1Y Return
8.87%
8.87%
Buy Reco %
56.25
56.25
DRREDDY
PE Ratio
18.92
18.92
1Y Return
7.16%
7.16%
Buy Reco %
51.61
51.61
LUPIN
PE Ratio
31.30
31.30
1Y Return
10.88%
10.88%
Buy Reco %
72.22
72.22
NURECA Forecast
NURECA Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
NURECA
NURECA
Income
Balance Sheet
Cash Flow
Annual Normal View
NURECA Income Statement
NURECA Income Statement
Annual Normal View
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 20.07 | 61.99 | 99.49 | 216.27 | 263.25 | 118.43 | 102.44 | 122.10 | 152.37 | |||||||||
Raw Materials | 15.68 | 50.16 | 67.49 | 120.01 | 159.55 | 44.76 | 56.23 | 74.97 | 136.14 | |||||||||
| Power & Fuel Cost | 0.02 | 0.04 | 0.01 | 0.16 | 0.20 | 0.13 | 0.18 | |||||||||||
| Employee Cost | 0.89 | 3.16 | 4.58 | 9.91 | 16.06 | 12.20 | 15.31 | |||||||||||
| Selling & Administrative Expenses | 11.12 | 21.17 | 44.93 | 51.71 | 29.99 | 24.91 | 30.25 | |||||||||||
| Operating & Other expenses | -9.35 | -2.12 | -17.62 | -21.29 | 35.32 | 8.67 | -3.51 | |||||||||||
EBITDA | 4.39 | 9.15 | 9.75 | 64.36 | 63.21 | -7.90 | 0.30 | 4.90 | 16.23 | |||||||||
| Depreciation/Amortization | 0.01 | 0.06 | 0.37 | 0.42 | 1.48 | 2.39 | 2.36 | 2.34 | 2.09 | |||||||||
| PBIT | 4.38 | 9.09 | 9.38 | 63.94 | 61.73 | -10.29 | -2.06 | 2.56 | 14.14 | |||||||||
| Interest & Other Items | 0.06 | 0.24 | 0.77 | 1.60 | 0.74 | 0.45 | 0.49 | 1.21 | 1.61 | |||||||||
| PBT | 4.32 | 8.85 | 8.61 | 62.34 | 60.99 | -10.74 | -2.55 | 1.35 | 12.53 | |||||||||
| Taxes & Other Items | 1.21 | 2.61 | 2.22 | 15.96 | 16.02 | -2.49 | -0.75 | 0.49 | 1.91 | |||||||||
| Net Income | 3.11 | 6.24 | 6.39 | 46.38 | 44.97 | -8.25 | -1.80 | 0.86 | 10.62 | |||||||||
| EPS | 0.64 | 891.43 | 912.86 | 92.11 | 44.97 | -8.25 | -1.80 | 0.86 | 10.62 | |||||||||
| DPS | 0.00 | 0.00 | 0.00 | 2.00 | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
NURECA Company Updates
NURECA Stock Peers
NURECA Past Performance & Peer Comparison
NURECA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Nureca Ltd | 315.88 | 1.40 | — |
| Sun Pharmaceutical Industries Ltd | 37.70 | 5.68 | 0.93% |
| Torrent Pharmaceuticals Ltd | 75.41 | 18.99 | 0.75% |
| Cipla Ltd | 20.59 | 3.47 | 1.19% |
NURECA Stock Price Comparison
Compare NURECA with any stock or ETFCompare NURECA with any stock or ETF
NURECA
NURECA Holdings
NURECA Shareholdings
NURECA Promoter Holdings Trend
NURECA Promoter Holdings Trend
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
NURECA Institutional Holdings Trend
NURECA Institutional Holdings Trend
No institutional holdings trend are available
NURECA Shareholding Pattern
NURECA Shareholding Pattern
NURECA Shareholding History
NURECA Shareholding History
Foreign Institutions
smallcases containing NURECA stock
smallcases containing NURECA stock
Looks like this stock is not in any smallcase yet.
NURECA Events
NURECA Events
NURECA Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
NURECA Dividend Trend
No dividend trend available
NURECA Upcoming Dividends
NURECA Upcoming Dividends
No upcoming dividends are available
NURECA Past Dividends
NURECA Past Dividends
Cash Dividend
Ex DateEx DateFeb 24, 2022
Interim
Interim | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Feb 24, 2022
Cash Dividend
Ex DateEx DateSep 21, 2021
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Sep 21, 2021
NURECA Stock News & Opinions
NURECA Stock News & Opinions
Articles & Videos
Spotlight
Nureca jumps on strong Q3 turnaround
Net profit stood at Rs 3.73 crore in Q3 FY26, compared with a loss of Rs 2.80 crore in Q3 FY25. On a sequential basis, PAT rose 2.8% from Rs 3.63 crore in Q2 FY26. Revenue from operations jumped 49.8% YoY to Rs 39.64 crore in Q3 FY26 from Rs 26.46 crore a year ago. Sequentially, revenue increased 5.0% from Rs 37.74 crore in Q2 FY26. Profit before tax stood at Rs 4.66 crore in Q3 FY26, compared with a loss of Rs 3.25 crore in the year-ago quarter, and was broadly flat sequentially versus Rs 4.60 crore in Q2 FY26. Total expenditure rose 19.4% YoY to Rs 36.39 crore during the quarter. Employee expenses increased 12.5% YoY to Rs 4.32 crore, while raw material costs surged 158.50% to Rs 10.34 crore from Rs 4.0 crore last year. Interest expense rose 55.56% YoY to Rs 0.28 crore from Rs 0.18 crore, while depreciation eased 7.4% YoY to Rs 0.50 crore. The management stated that the financial performance was primarily driven by enhanced operational efficiencies, improved sourcing strategies, and strengthened manufacturing capabilities. Focused cost optimization, tighter supply chain controls, and productivity improvements enabled better margins, while scalable manufacturing capabilities supported sustainable growth and consistent execution. Nureca continues to operate a digital-first, asset-light model, with over 90% of revenues generated through online channels. The company remains debt-free and maintains a healthy liquidity position. Nureca is a digital healthcare company focused on home healthcare and wellness products. Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Earnings
Nureca reports consolidated net profit of Rs 3.73 crore in the December 2025 quarter
Net profit of Nureca reported to Rs 3.73 crore in the quarter ended December 2025 as against net loss of Rs 2.80 crore during the previous quarter ended December 2024. Sales rose 49.81% to Rs 39.64 crore in the quarter ended December 2025 as against Rs 26.46 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales39.6426.46 50 OPM %8.20-15.19 - PBDT5.16-2.71 LP PBT4.66-3.25 LP NP3.73-2.80 LP Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Nureca to table results
Nureca will hold a meeting of the Board of Directors of the Company on 17 January 2026.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Nureca board approves buyback of shares aggregating Rs 19.14 cr
The board of Nureca at its meeting held on 28 November 2025 has approved buyback of 5.80 lakh equity shares of the company at a price of Rs 330 for an aggregate amount of Rs 19.14 crore. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Nureca fixes record date for buyback of shares
Nureca has fixed 12 December 2025 as record date for buyback of equity shares. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Nureca to consider Buyback
Nureca will hold a meeting of the Board of Directors of the Company on 28 November 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Nureca to hold board meeting
Nureca will hold a meeting of the Board of Directors of the Company on 10 November 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Nureca reports consolidated net profit of Rs 3.63 crore in the September 2025 quarter
Net profit of Nureca reported to Rs 3.63 crore in the quarter ended September 2025 as against net loss of Rs 0.48 crore during the previous quarter ended September 2024. Sales rose 21.00% to Rs 37.74 crore in the quarter ended September 2025 as against Rs 31.19 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales37.7431.19 21 OPM %8.66-7.57 - PBDT5.130.55 833 PBT4.60-0.08 LP NP3.63-0.48 LP Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Nureca to hold board meeting
Nureca will hold a meeting of the Board of Directors of the Company on 16 October 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Nureca consolidated net profit declines 51.20% in the June 2025 quarter
Net profit of Nureca declined 51.20% to Rs 0.81 crore in the quarter ended June 2025 as against Rs 1.66 crore during the previous quarter ended June 2024. Sales rose 68.62% to Rs 34.18 crore in the quarter ended June 2025 as against Rs 20.27 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales34.1820.27 69 OPM %-1.64-11.64 - PBDT1.763.28 -46 PBT1.232.62 -53 NP0.811.66 -51 Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 4.18%, vs industry avg of 10.04%
Over the last 5 years, market share decreased from 0.04% to 0.03%
Over the last 5 years, net income has grown at a yearly rate of -33.04%, vs industry avg of 20.02%